StreetInsider.com News Articles

Ladenburg Thalmann Assumes Elicio Therapeutics (ELTX) at Buy

Thu, 18 Jun 2026 06:35:58 -0400

Ladenburg Thalmann analyst Kevin DeGeeter assumes coverage on Elicio Therapeutics (NASDAQ: ELTX) with a Buy rating and a price target of $12.00.

For an analyst ratings summary and ratings history on Elicio Therapeutics click here. For more ratings news on Elicio Therapeutics click here.

Shares of Elicio Therapeutics closed at $4.71 yesterday.

Form 8-K Elicio Therapeutics, For: Jun 17

Wed, 17 Jun 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26657163.html

Form 8-K Elicio Therapeutics, For: Jun 17

Wed, 17 Jun 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26657163.html

Elicio reports complete responses in pancreatic cancer after ELI-002 7P

Wed, 17 Jun 2026 08:00:50 -0400

Elicio Therapeutics, Inc. (Nasdaq: ELTX) reported that three patients with metastatic pancreatic cancer who progressed after treatment with ELI-002 7P in its Phase 2 AMPLIFY-7P study subsequently achieved confirmed complete radiographic and complete metabolic responses after receiving nivolumab-based therapy.

According to the company, two of the three patients maintained complete responses for at least eight months, with one ongoing response exceeding 13 months. All three patients also showed concurrent normalization of tumor biomarker CA19-9 levels and persistent mutant KRAS-specific T cell responses.

All three patients were microsatellite stable and mismatch repair proficient, a population that has historically shown limited responsiveness to immune

Elicio reports complete responses in pancreatic cancer after ELI-002 7P

Wed, 17 Jun 2026 08:00:50 -0400

All three patients were microsatellite stable and mismatch repair proficient, a population that has historically shown limited responsiveness to immune

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Wed, 17 Jun 2026 08:00:00 -0400

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy
Complete responses (“CRs”) are rarely (0-8%) observed in metastatic pancreatic cancer in published studies evaluating chemotherapy-, checkpoint inhibitor-, and RAS inhibitor-based regimens
ELI-002 7P-induced mutant KRAS(“mKRAS”)-specific T cells may synergize with checkpoint inhibition to allow deep antitumor responses in a tumor type previously considered refractory to immunotherapy
Elicio believes these post-study observations build on mechanistic validation from prior AMPLIFY studies and support evaluation of ELI-002 7P

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Wed, 17 Jun 2026 08:00:00 -0400

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy
Complete responses (“CRs”) are rarely (0-8%) observed in metastatic pancreatic cancer in published studies evaluating chemotherapy-, checkpoint inhibitor-, and RAS inhibitor-based regimens
ELI-002 7P-induced mutant KRAS(“mKRAS”)-specific T cells may synergize with checkpoint inhibition to allow deep antitumor responses in a tumor type previously considered refractory to immunotherapy
Elicio believes these post-study observations build on mechanistic validation from prior AMPLIFY studies and support evaluation of ELI-002 7P

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Wed, 17 Jun 2026 08:00:00 -0400

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy
Complete responses (“CRs”) are rarely (0-8%) observed in metastatic pancreatic cancer in published studies evaluating chemotherapy-, checkpoint inhibitor-, and RAS inhibitor-based regimens
ELI-002 7P-induced mutant KRAS(“mKRAS”)-specific T cells may synergize with checkpoint inhibition to allow deep antitumor responses in a tumor type previously considered refractory to immunotherapy
Elicio believes these post-study observations build on mechanistic validation from prior AMPLIFY studies and support evaluation of ELI-002 7P

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Wed, 17 Jun 2026 08:00:00 -0400

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy
Complete responses (“CRs”) are rarely (0-8%) observed in metastatic pancreatic cancer in published studies evaluating chemotherapy-, checkpoint inhibitor-, and RAS inhibitor-based regimens
ELI-002 7P-induced mutant KRAS(“mKRAS”)-specific T cells may synergize with checkpoint inhibition to allow deep antitumor responses in a tumor type previously considered refractory to immunotherapy
Elicio believes these post-study observations build on mechanistic validation from prior AMPLIFY studies and support evaluation of ELI-002 7P

Jones Trading Downgrades Elicio Therapeutics (ELTX) to Hold

Mon, 15 Jun 2026 16:11:59 -0400

Jones Trading analyst Boris Peaker downgraded Elicio Therapeutics (NASDAQ: ELTX) from Buy to Hold.

For an analyst ratings summary and ratings history on Elicio Therapeutics click here. For more ratings news on Elicio Therapeutics click here.

Shares of Elicio Therapeutics closed at $14.85 yesterday.

Elicio Therapeutics (ELTX) PT Raised to $17.50 at Rodman & Renshaw

Mon, 15 Jun 2026 09:46:23 -0400

Rodman & Renshaw analyst Michael King Jr. raised the price target on Elicio Therapeutics (NASDAQ: ELTX) to $17.50 (from $17.00) while maintaining a Buy rating.

The analyst comments "Following Elicio Therapeutics' release of topline results from the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC), we are revising our price target to $17.50 from $17 and reiterating our BUY rating. While the study did not meet its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat (ITT) population, we believe the dataset is substantially more informative than a binary read. In our

Elicio Therapeutics (ELTX) PT Raised to $17.50 at Rodman & Renshaw

Mon, 15 Jun 2026 09:46:23 -0400

Rodman & Renshaw analyst Michael King Jr. raised the price target on Elicio Therapeutics (NASDAQ: ELTX) to $17.50 (from $17.00) while maintaining a Buy rating.

Elicio Therapeutics (ELTX) PT Raised to $17.50 at Rodman & Renshaw

Mon, 15 Jun 2026 09:46:23 -0400

Rodman & Renshaw analyst Michael King Jr. raised the price target on Elicio Therapeutics (NASDAQ: ELTX) to $17.50 (from $17.00) while maintaining a Buy rating.

H.C. Wainwright Defending Elicio Therapeutics (ELTX) Amid 71% Drop

Mon, 15 Jun 2026 09:44:45 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $23.00 price target on Elicio Therapeutics (NASDAQ: ELTX).

Sees pullback yielding an attractive entry point.

For an analyst ratings summary and ratings history on Elicio Therapeutics click here. For more ratings news on Elicio Therapeutics click here.

Shares of Elicio Therapeutics closed at $14.85 yesterday.

H.C. Wainwright Defending Elicio Therapeutics (ELTX) Amid 71% Drop

Mon, 15 Jun 2026 09:44:45 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $23.00 price target on Elicio Therapeutics (NASDAQ: ELTX).

Sees pullback yielding an attractive entry point.

For an analyst ratings summary and ratings history on Elicio Therapeutics click here. For more ratings news on Elicio Therapeutics click here.

Shares of Elicio Therapeutics closed at $14.85 yesterday.

Form 8-K Elicio Therapeutics, For: Jun 15

Mon, 15 Jun 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260615/26645200.html

Form 8-K Elicio Therapeutics, For: Jun 15

Mon, 15 Jun 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260615/26645200.html

Elicio's pancreatic cancer drug fails phase 2 study endpoint

Mon, 15 Jun 2026 07:00:13 -0400

Elicio Therapeutics Inc. (NASDAQ: ELTX) announced that its Phase 2 AMPLIFY-7P study of ELI-002 7P did not meet its primary endpoint of disease-free survival in patients with pancreatic cancer.

The study enrolled 144 patients across 24 U.S. sites and evaluated ELI-002 7P versus observation in patients with resected Stage I-III mutant KRAS-driven pancreatic ductal adenocarcinoma who had completed surgery and standard therapy.

The company reported an imbalance in baseline characteristics between treatment groups, with the ELI-002 7P arm containing a higher proportion of patients with R1 resection status, an adverse prognostic factor. The ELI-002 7P arm had 19% R1 resected patients compared

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Mon, 15 Jun 2026 07:00:00 -0400

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population.
Randomization balanced most prognostic factors between arms. However, the ELI-002 7P arm had a higher proportion of R1 resected (higher residual disease, tumor present at or within 1 mm of surgical margin) patients compared with the observation arm (ELI-002 7P 19% vs. observation 10%), a known adverse prognostic factor for recurrence.
R1 patients have increased relapse-risk, implying that this imbalance meaningfully and negatively impacted the ELI-002 arm.
Post-hoc analysis identified a stronger DFS hazard ratio in the R0, completely resected population (post-hoc HR 0.65, p=0.048, ELI-002 7P

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Mon, 15 Jun 2026 07:00:00 -0400

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population.
Randomization balanced most prognostic factors between arms. However, the ELI-002 7P arm had a higher proportion of R1 resected (higher residual disease, tumor present at or within 1 mm of surgical margin) patients compared with the observation arm (ELI-002 7P 19% vs. observation 10%), a known adverse prognostic factor for recurrence.
R1 patients have increased relapse-risk, implying that this imbalance meaningfully and negatively impacted the ELI-002 arm.
Post-hoc analysis identified a stronger DFS hazard ratio in the R0, completely resected population (post-hoc HR 0.65, p=0.048, ELI-002 7P

B.Riley Starts Elicio Therapeutics (ELTX) at Buy

Wed, 10 Jun 2026 08:28:29 -0400

B.Riley analyst Mayank Mamtani initiates coverage on Elicio Therapeutics (NASDAQ: ELTX) with a Buy rating and a price target of $27.00.

For an analyst ratings summary and ratings history on Elicio Therapeutics click here. For more ratings news on Elicio Therapeutics click here.

Shares of Elicio Therapeutics closed at $14.20 yesterday.

Elicio Therapeutics publishes research on AMP-DNA adjuvant technology

Mon, 01 Jun 2026 08:04:24 -0400

Elicio Therapeutics Inc. (NASDAQ: ELTX) announced the publication of research describing its AMP-DNA adjuvant candidates in the peer-reviewed journal Science Advances. The manuscript details preclinical studies of novel adjuvants built from the company's lymph node-targeting Amphiphile platform technology.

The published research, titled "Lymph node targeted DNA engages TBK1/IFN-I driven innate immunity to induce potent T cell responses and durable memory in mice and NHPs," examines the ability of AMP-DNA adjuvants to generate immune responses through targeted delivery to lymph nodes and activation of innate immune pathways.

According to the study findings, AMP-DNA adjuvants demonstrated superior performance compared to current clinical and commercial

Elicio Therapeutics publishes research on AMP-DNA adjuvant technology

Mon, 01 Jun 2026 08:04:24 -0400

According to the study findings, AMP-DNA adjuvants demonstrated superior performance compared to current clinical and commercial

Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology

Mon, 01 Jun 2026 08:00:00 -0400

Preclinical data demonstrate robust T cell activation, durable immune memory, and lymph node-targeted mechanism supporting next-generation immunotherapies

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of a peer-reviewed manuscript in Science Advances, published by the American Association for the Advancement of Science, describing a series of novel AMP-DNA adjuvant candidates built from the lymph node-targeting Amphiphile (“AMP”) platform technology.

The manuscript, titled “Lymph node targeted DNA engages TBK1/IFN-I driven innate immunity

Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology

Mon, 01 Jun 2026 08:00:00 -0400

Preclinical data demonstrate robust T cell activation, durable immune memory, and lymph node-targeted mechanism supporting next-generation immunotherapies

The manuscript, titled “Lymph node targeted DNA engages TBK1/IFN-I driven innate immunity